Aurion Biotech, a clinical-stage biotech company aiming to restore vision to millions of patients with regenerative therapies, announced on Wednesday that AURN001, an allogeneic cell therapy for corneal edema, has secured both Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA).
AURN001 is the first therapy of its kind to achieve this dual designation for the treatment of corneal edema secondary to corneal endothelial disease.
BTD expedites development for treatments with promising clinical data, while RMAT recognizes the potential of regenerative therapies for unmet medical needs. These designations aim to accelerate AURN001's path to market, leveraging positive results from ongoing Phase 1/2 trials.
AURN001 has already received regulatory approval in Japan.
Novavax COVID-19 vaccine approved in US
Cantargia secures US patent for nadunolimab combination therapies
European Commission approves Bio-Thera Solutions' BAT2206
INOVIO to begin rolling submission of BLA for INO-3107
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Orsini named by Ionis as exclusive specialty pharmacy partner for DAWNZERA (donidalorsen)
Curasight's uTREAT clinical trial application approved in Europe
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Innovent Biologics receives approval over squamous cell lung cancer study
Crinetics Pharmaceuticals' atumelnant granted US FDA Orphan Drug Designation
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Hamlet BioPharma completes Phase II study of Alpha1H in non-muscle invasive bladder cancer